Abstract:
Methods for diagnosing and treating a cancer or a tumor in a patient are provided. The methods can comprise the steps of obtaining a biological sample from the patient and analyzing the sample for the presence or absence of Coiled Coil Helix Cristae Morphology 1 protein (CHCM1). A patient is diagnosed with cancer or a tumor provided that CHCM1 is overexpressed. The diagnosed patient is treated by administering a cancer or tumor treatment. The methods can also comprise the steps of obtaining a sample of cancer or tumor cells from the patient, determining a level of CHCM1 expression in the sample of cancer or tumor cells, and administering to the patient a compound for reducing the expression of CHCM1 or for blocking or inhibiting function of CHCM1.
Abstract:
A gasifier system includes a reactor for receiving a wet feedstock which has a base and a container rotatably connected to the base such that a rotation of the container causes a mixing of the feedstock in an interior of the reactor. The interior is bounded by the base and the container. A space between the base and the container allows an entry of oxygen into the interior. The space has a dimension such that the feedstock is fully oxidized in a combustion area adjacent the base and such that the feedstock avoids combustion in a remainder of the interior. The reactor has a longitudinal axis inclined at an inclination angle relative to a horizontal line to promote the mixing of the feedstock in the interior.
Abstract:
An automatic facial action coding system and method can include processing an image to identify a face in the image, to detect and align one or more facial features shown in the image, and to define one or more windows on the image. One or more distributions of pixels and color intensities can be quantified in each of the one or more windows to derive one or more two-dimensional intensity distributions of one or more colors within the window. The one or more two-dimensional intensity distributions can be processed to select image features appearing in the one or more windows and to classify one or more predefined facial actions on the face in the image. A facial action code score that includes a value indicating a relative amount of the predefined facial action occurring in the face in the image can be determined for the face in the image for each of the one or more predefined facial actions.
Abstract:
The invention relates to nanomaterials and assemblies including, a micrometer-scale spherical aggregate comprising: a plurality of one-dimensional nanostructures comprising titanium and oxygen, wherein the one-dimensional nanostructures radiate from a hollow central core thereby forming a spherical aggregate.
Abstract:
The invention relates to electrochemical electrodes containing branched nanostructures having increased surface area and flexibility. These branched nanostructures allow for higher anode density, resulting in the creation of smaller, longer-lasting, more efficient batteries which require less area for the same charging capacity. Also disclosed are methods for creating said branched nanostructures and electrodes.
Abstract:
Disclosed are RNA targeting compounds having the formula: wherein j is an integer from 1 to 100; each i is the same or different and is zero or an integer from 1 to 100; each Z1 represents the same or different linking moiety; each R1 is the same or different and represents an alkyl group or an aryl group; each Q1 represents the same or different RNA binding ligand; Q2 is an alkyl group; Q3 is a halogen, an alkyl group, an aryl group, or an amine. Also disclosed are RNA targeting compounds that include a polymer backbone and two or more pendant RNA binding ligands that are bound to the polymer backbone. Methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed, as are compounds that can be used to prepare the subject RNA targeting compounds.
Abstract:
An apparatus and method are provided for integrating TSVs into devices prior to device contacts processing. The apparatus includes a semiconducting layer; one or more CMOS devices mounted on a top surface of the semiconducting layer; one or more TSVs integrated into the semiconducting layer of the device wafer; at least one metal layer applied over the TSVs; and one or more bond pads mounted onto a top layer of the at least one metal layer, wherein the at least one metal layer is arranged to enable placement of the one or more bond pads at a specified location for bonding to a second device wafer. The method includes obtaining a wafer of semiconducting material, performing front end of line processing on the wafer; providing one or more TSVs in the wafer; performing middle of line processing on the wafer; and performing back end of line processing on the wafer.
Abstract:
Methods for LED generated low-level light therapy (LLLT) in the red, blue, and IR ranges are described to effectively inhibit fibroblast proliferation in vitro without altering viability, and may be used as therapy for the treatment of scars and other proliferative skin diseases.
Abstract:
Embodiments of films and material layers comprising PEDOT. These embodiments are the result of methods that utilize polymerization processes including vapor phase polymerization (VPP) to form the conductive film comprising PEDOT. In one embodiment, the film can result from a method that includes steps for depositing a coating solution onto a substrate, exposing the substrate to a monomer source, and cleaning the subsrate after polymerization. The coating solution can comprise an initiating oxidant, which facilitates growth of PEDOT from 3,4 ethylenedioxythiophene (EDOT), as well as a quenching agent that neutralizes acid that results from polymerization.
Abstract:
Provided are methods and compositions for determining whether an individual has Sjögren's disease (SD). The method entails determining in a biological sample from the individual the presence of antibodies directed to salivary gland protein 1 (SP-1), parotid secretory protein (PSP), carbonic anhydrase 6 (CA6), or determining a combination of the antibodies. Determining that the individual has SD is based on the presence of the antibodies. The method provides for detection of early SD. Kits for antibody detection containing the antigens to which the antibodies of SD patients are directed are also provided.